SK13472002A3 - Derivát 2-guanidíno-4-arylchinazolínu ako NHE-3 inhibítor, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents
Derivát 2-guanidíno-4-arylchinazolínu ako NHE-3 inhibítor, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje Download PDFInfo
- Publication number
- SK13472002A3 SK13472002A3 SK1347-2002A SK13472002A SK13472002A3 SK 13472002 A3 SK13472002 A3 SK 13472002A3 SK 13472002 A SK13472002 A SK 13472002A SK 13472002 A3 SK13472002 A3 SK 13472002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- quinazolinylguanidine
- chloro
- phenyl
- methylphenyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019062A DE10019062A1 (de) | 2000-04-18 | 2000-04-18 | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| PCT/EP2001/003281 WO2001079186A1 (de) | 2000-04-18 | 2001-03-22 | 2-guanidino-4-aryl-chinazoline als nhe-3-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK13472002A3 true SK13472002A3 (sk) | 2003-02-04 |
Family
ID=7639090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1347-2002A SK13472002A3 (sk) | 2000-04-18 | 2001-03-22 | Derivát 2-guanidíno-4-arylchinazolínu ako NHE-3 inhibítor, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040224965A1 (de) |
| EP (1) | EP1274691A1 (de) |
| JP (1) | JP2004501082A (de) |
| KR (1) | KR20030011789A (de) |
| CN (1) | CN1422260A (de) |
| AR (1) | AR028914A1 (de) |
| AU (1) | AU2001293373A1 (de) |
| BR (1) | BR0109867A (de) |
| CA (1) | CA2406161A1 (de) |
| DE (1) | DE10019062A1 (de) |
| HU (1) | HUP0300909A3 (de) |
| MX (1) | MXPA02010264A (de) |
| NO (1) | NO20024997L (de) |
| PL (1) | PL356559A1 (de) |
| RU (1) | RU2002130246A (de) |
| SK (1) | SK13472002A3 (de) |
| WO (1) | WO2001079186A1 (de) |
| ZA (1) | ZA200209274B (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10043667A1 (de) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
| US6911453B2 (en) * | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
| IL162316A0 (en) * | 2001-12-05 | 2005-11-20 | Aventis Pharma Gmbh | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t |
| DE10161767A1 (de) * | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
| DE10163239A1 (de) * | 2001-12-21 | 2003-07-10 | Aventis Pharma Gmbh | Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament |
| US20030187045A1 (en) | 2001-12-21 | 2003-10-02 | Uwe Heinelt | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic |
| DE10163914A1 (de) * | 2001-12-22 | 2003-07-03 | Aventis Pharma Gmbh | Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
| DE10163992A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | 4-Aryl-chinazoline |
| US7049333B2 (en) | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| DE10304374A1 (de) | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10341240A1 (de) | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE102005044817A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| ATE479679T1 (de) | 2007-06-28 | 2010-09-15 | Sanofi Aventis Us Llc | Verfahren zur herstellung von n-(2-chlor-4-methyl-3-thienyl)-1h-benzimidazol- 2-amin hydrochlorid und zwischenprodukte dafür |
| EP2342178B1 (de) | 2008-09-02 | 2016-09-28 | Sanofi | Substituierte aminoindane und analoga sowie ihre pharmazeutische verwendung |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| PL2384318T3 (pl) | 2008-12-31 | 2018-04-30 | Ardelyx, Inc. | Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN104902930A (zh) | 2012-08-21 | 2015-09-09 | 阿德利克斯公司 | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 |
| WO2014169094A2 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| ME03311B (de) | 2014-07-25 | 2019-10-20 | Taisho Pharmaceutical Co Ltd | Mit heteroaryl substituierte phenyltetrahydroisochinolinverbindung |
| MX2019008170A (es) | 2017-01-09 | 2020-02-07 | Ardelyx Inc | Compuestos útiles para tratar transtornos del tracto gastrointestinal. |
| AU2018206479B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Inhibitors of NHE-mediated antiport |
| CA3071992A1 (en) | 2017-08-04 | 2019-03-28 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for treating hyperkalemia |
| EP3921327B1 (de) | 2019-02-07 | 2023-04-05 | Ardelyx, Inc. | Glycyrrhetinsäurederivate zur behandlung von hyperkaliämie |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131187A (en) * | 1964-04-28 | Certain z-guantoino-x-aryl-quinazolines |
-
2000
- 2000-04-18 DE DE10019062A patent/DE10019062A1/de not_active Withdrawn
-
2001
- 2001-03-22 PL PL01356559A patent/PL356559A1/xx unknown
- 2001-03-22 US US10/257,636 patent/US20040224965A1/en not_active Abandoned
- 2001-03-22 MX MXPA02010264A patent/MXPA02010264A/es unknown
- 2001-03-22 WO PCT/EP2001/003281 patent/WO2001079186A1/de not_active Application Discontinuation
- 2001-03-22 CN CN01807951A patent/CN1422260A/zh active Pending
- 2001-03-22 AU AU2001293373A patent/AU2001293373A1/en not_active Abandoned
- 2001-03-22 KR KR1020027011796A patent/KR20030011789A/ko not_active Application Discontinuation
- 2001-03-22 CA CA002406161A patent/CA2406161A1/en not_active Abandoned
- 2001-03-22 RU RU2002130246/04A patent/RU2002130246A/ru not_active Application Discontinuation
- 2001-03-22 EP EP01969043A patent/EP1274691A1/de not_active Withdrawn
- 2001-03-22 HU HU0300909A patent/HUP0300909A3/hu unknown
- 2001-03-22 JP JP2001576787A patent/JP2004501082A/ja active Pending
- 2001-03-22 SK SK1347-2002A patent/SK13472002A3/sk unknown
- 2001-03-22 BR BR0109867-5A patent/BR0109867A/pt not_active IP Right Cessation
- 2001-04-18 AR ARP010101808A patent/AR028914A1/es not_active Application Discontinuation
-
2002
- 2002-10-17 NO NO20024997A patent/NO20024997L/no not_active Application Discontinuation
- 2002-11-14 ZA ZA200209274A patent/ZA200209274B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2406161A1 (en) | 2002-10-16 |
| CN1422260A (zh) | 2003-06-04 |
| JP2004501082A (ja) | 2004-01-15 |
| MXPA02010264A (es) | 2003-04-25 |
| BR0109867A (pt) | 2003-06-03 |
| NO20024997D0 (no) | 2002-10-17 |
| HUP0300909A2 (hu) | 2003-10-28 |
| ZA200209274B (en) | 2004-02-16 |
| RU2002130246A (ru) | 2004-03-27 |
| US20040224965A1 (en) | 2004-11-11 |
| PL356559A1 (en) | 2004-06-28 |
| NO20024997L (no) | 2002-10-17 |
| DE10019062A1 (de) | 2001-10-25 |
| AU2001293373A1 (en) | 2001-10-30 |
| KR20030011789A (ko) | 2003-02-11 |
| EP1274691A1 (de) | 2003-01-15 |
| WO2001079186A1 (de) | 2001-10-25 |
| AR028914A1 (es) | 2003-05-28 |
| HUP0300909A3 (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK13472002A3 (sk) | Derivát 2-guanidíno-4-arylchinazolínu ako NHE-3 inhibítor, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
| US20050020612A1 (en) | 4-Aryliquinazolines and the use thereof as nhe-3 inhibitors | |
| CZ2003858A3 (cs) | Derivát 2-guanidino-4-arylchinazolinu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje | |
| KR20040065233A (ko) | ２-구아니디노-４-헤테로사이클일퀴나졸린 | |
| JP5249918B2 (ja) | 置換された１−アミノ−４−フェニル−ジヒドロイソキノリン、それらの製造法、それらの薬剤としての使用、およびそれらを含有する薬剤 | |
| JP2005533038A (ja) | 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬 | |
| EP1664058B1 (de) | Substituierte thienoimidazole, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltende medikamente | |
| EP1999112B1 (de) | Substituierte 2-amino-4-phenyl-dihydrochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament | |
| CZ274495A3 (en) | Derivative of alkyl-5-methylsulfonyl benzoguanidine, process of its preparation and pharmaceutical composition containing thereof | |
| MXPA05002963A (es) | Compuestos quimicos. | |
| SK512000A3 (en) | Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists |